Cardiogenesis Corporation

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

Retrieved on: 
Tuesday, July 27, 2021
Cardiology, Biotechnology, Pharmaceutical, Surgery, Health, FDA, Genetics, Clinical trials, Medical specialties, Circulatory system, Cardiac surgery, Clinical medicine, Coronary artery bypass surgery, Angina, Coronary arteries, Heart diseases, Cardiogenesis Corporation, Coronary artery disease, XC001, the EXACT Study, Chronic Refractory Angina, XyloCor, XC001, THE EXACT STUDY, CHRONIC REFRACTORY ANGINA, XYLOCOR

XyloCor also confirms that it plans to submit an additional Phase 2 clinical study to the U.S. Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21.

Key Points: 
  • XyloCor also confirms that it plans to submit an additional Phase 2 clinical study to the U.S. Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21.
  • It is very exciting to now move forward with exploring XC001s potential in the Phase 2 portion of EXACT as a one-time therapy for patients with refractory angina.
  • XyloCor commenced the EXACT Trial, a Phase 1/2 study of XC001 in chronic refractory angina, in 2020.
  • The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm, dose-escalation trial.

XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina

Retrieved on: 
Tuesday, July 21, 2020
Health, Genetics, Clinical trials, Pharmaceutical, Cardiology, Biotechnology, Branches of biology, Biology, Life sciences, RTT, Aging-associated diseases, Coronary artery disease, Angina, Therapy, Gene therapy, Coronary arteries, Variant angina, Cardiogenesis Corporation, the EXACT Trial, XyloCor

XyloCor Therapeutics today announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.

Key Points: 
  • XyloCor Therapeutics today announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.
  • XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply.
  • The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) is a Phase 1/2 first-in-human, multicenter, open-label, single arm dose escalation trial evaluating the safety, tolerability and efficacy of XC001 at six months in patients who suffer from chronic angina caused by coronary artery disease with no other treatment options.
  • XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease.